Research programme: cancer therapeutics - Sapphire Biotech
Alternative Names: SPX-013; SPX-014Latest Information Update: 28 Jan 2022
At a glance
- Originator Sapphire Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cancer metastases
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Cancer-metastases in USA (PO)
- 18 Mar 2020 Sapphire Biotech has been acquired by Axim Biotech